Knight Therapeutics Inc. focuses on building a diverse portfolio of innovative pharmaceutical products without taking on the risks of early-stage drug discovery. The company's product lineup includes over 150 medicines spanning therapeutic areas such as oncology, infectious diseases, and other specialty care settings. Knight sells its products directly to hospitals, clinics, pharmacies, and both public and private healthcare systems. The company significantly expanded its geographic footprint across 10 Latin American countries through the acquisition of Grupo Biotoscana in 2019. By acting as a bridge between drug developers and local healthcare markets, Knight provides end-to-end commercialization, marketing, and regulatory services for its partners.
